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ABSTRACT: Technological developments in gene editing raise high expectations for clinical applications, ﬁrst of all for somatic gene editing
but in theory also for germline gene editing (GLGE). GLGE is currently not allowed in many countries. This makes clinical applications in these
countries impossible now, even if GLGE would become safe and effective. What were the arguments behind this legislation, and are they still
convincing? If a technique can help to avoid serious genetic disorders, in a safe and effective way, would this be a reason to reconsider earlier
standpoints? The European Society of Human Reproduction and Embryology (ESHRE) and the European Society of Human Genetics (ESHG)
together developed a Background document and Recommendations to inform and stimulate ongoing societal debates. After consulting its
membership and experts, this ﬁnal version of the Recommendations was endorsed by the Executive Committee and the Board of the
respective Societies in May 2017. Taking account of ethical arguments, we argue that both basic and pre-clinical research regarding human
GLGE can be justiﬁed, with conditions. Furthermore, while clinical GLGE would be totally premature, it might become a responsible interven-
tion in the future, but only after adequate pre-clinical research. Safety of the child and future generations is a major concern. Future discus-
sions must also address priorities among reproductive and potential non-reproductive alternatives, such as PGD and somatic editing, if that
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would be safe and successful. The prohibition of human germline modiﬁcation, however, needs renewed discussion among relevant stake-
holders, including the general public and legislators.
Key words: human germline gene editing / ESHRE / ESHG / ethics / legislation / professional policy / recommendations / responsible
innovation
Introduction
Recent research and expected further studies in gene editing raise high
expectations, especially regarding possible therapeutic applications in
humans. Most promising is the prospect of somatic gene editing, which
may prove to be a ‘game changer’ not only in the treatment of a whole
range of serious hereditary disorders, especially Mendelian ones, but
also in the treatment of cancer and infectious diseases. Over 5000
Mendelian diseases are identiﬁed whereas currently treatment is avail-
able for only a small minority of these. At the same time, the possibility
of a future application in the human germline raises serious concerns.
In previous decades, legislation has been adopted that does not allow
changes to the human germline. What were the arguments behind this
legislation, do they still apply and are they still convincing? If a tech-
nique can help to avoid serious genetic disorders (with severe effects
on quality of life or life span) in a safe and effective way, would this be
a reason to reconsider earlier standpoints? Discussion with relevant
stakeholders is needed, including professional health care workers,
patients and different groups of lay public, plus legal and ethical
experts. Recently, initiatives have been taken worldwide to exchange
views and re-ignite the debate about responsible governance and
approaches to innovation using human gene editing. The European
Society of Human Genetics (ESHG) and the European Society of
Human Reproduction and Embryology (ESHRE) consider it to be their
professional responsibility to contribute to further discussion by means
of a set of Recommendations, based on a Background document,
focusing on human germline gene editing (GLGE).
The aim of this contribution is to inform and stimulate ongoing soci-
etal debates, as well as provide guidance, taking into account: the tech-
nical aspects of GLGE, its different possible applications, relevant
clinical experience regarding the handling of reproductive risk, legal
regulations, and the ethical and societal issues and concerns linked
with GLGE. Because of the importance of the latter, both ESHG and
ESHRE invited their relevant committees (respectively, the Public and
Professional Policy Committee of ESHG, and the Ethics Committee of
ESHRE) to take the lead in writing the Background document and
Recommendations. Drafts were prepared by a joint writing group and
were discussed in both committees and in a joint meeting of the two
societies on 20 September 2016. Next, a draft of the
Recommendations was posted online from 17 October until 2
December 2016 and was presented at the American Society of
Human Genetics meeting in Vancouver. The Background document
and the Recommendations have been posted online to solicit com-
ments from the membership of both ESHG and ESHRE from 3 April
until 8 May 2017. The authors integrated the suggestions where
appropriate and the Recommendations were endorsed by the Board
of ESHG and the Executive Committee of ESHRE. This Document is of
a provisional nature, and is to be re-evaluated regularly, taking account
of relevant scientiﬁc developments, possible future clinical experiences
and evolving discussions in society as a whole as well as ethical reﬂec-
tion. The Recommendations should be understood against the argu-
mentation provided in the Background document (De Wert et al.
2017a,b). We strongly recommend also reading this Background docu-
ment and will refer to relevant sections below.
Recommendations
In preparing this Document, it was considered crucial to make a dis-
tinction between non-reproductive GLGE in basic research, non-
reproductive GLGE in pre-clinical research and possible future clinical
(reproductive) GLGE.
Non-reproductive germline gene editing in
basic research
Non-reproductive GLGE primarily concerns the context of basic
research. Although a sharp demarcation between basic research and
pre-clinical research is difﬁcult to make, basic research in this context
is characterized by a focus on fundamental questions regarding human
embryology and the methods applied in gene editing. Reproductive
treatments in health care and adequate patient counselling may be
served by a better knowledge of early embryo development. There
are good reasons to allow basic research in this area, subject of course
WHATDOES THIS MEAN FOR PATIENTS?
This paper contains Recommendations from ESHRE and ESHG concerning human gene editing of sperm, oocytes and embryos.
The Societies recommend that there are good reasons for more research into this area, as this approach has potential for helping people with
hereditary diseases. However, it would make permanent changes to the genetic makeup of edited offspring, so any research into this method of
gene editing must be carefully monitored and overseen. Only after such research had ensured the safety and efﬁcacy of the method would it
even be considered for clinical use to help people with hereditary diseases. There would need to be provision for follow-up studies and further
research, as well as proper public debate.
The details of the initial recommendations from the societies are contained in this paper, but they make it clear that these are likely to need
re-evaluation in the future.
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to societal oversight and taking account of relevant ethical guidelines
and (inter-)national legal regulations.
The research use of human somatic cells and (precursor cells of)
gametes is less controversial than human embryo research in vitro. The
Oviedo Convention categorically prohibits the making of human
embryos speciﬁcally for research purposes (‘research embryos’). Several
European countries rely on the use of spare embryos left over after IVF
procedures only. If necessary and possible, the use of spare embryos
over embryos created for research should be the preferred option.
However, also from an ethical point of view, a prohibition to make such
embryos may be contested. As elaborated in the Background document,
the making of research embryos could be morally justiﬁed, subject to
ethical, legal and societal oversight, if the research question cannot be
adequately addressed on the basis of spare embryos only and if research
embryos are necessary to reach the aim(s) of scientiﬁcally sound and
robust research. Given the sensitivity of human germline interventions,
the speciﬁc consent of the providers of the gametes and embryos to
such basic research use should be obtained.
Non-reproductive germline gene editing
in pre-clinical research
Only after acquiring robust knowledge from basic research might future
clinical applications be considered, which would require further societal
and professional discussions. Both for scientiﬁc and moral reasons, as a
precondition for any potential clinical applications of GLGE, adequate
pre-clinical research on GLGE is necessary. Pre-clinical research, involv-
ing both animal and human embryo research, is an important element of
the moral framework for the introduction of new, experimental, repro-
ductive technologies generally. Given the speciﬁc sensitivity of GLGE,
such research would have to take place under ongoing monitoring and
societal oversight. Pre-clinical GLGE research would involve investigation
of the safety (e.g. possible off-target effects or epigenetic effects) and
effectiveness of gene editing in view of possible future reproductive
applications of GLGE in gametes, zygotes or preimplantation embryos.
Such research is important in order to identify and eliminate, or at least
reduce, avoidable risks for any future children thus conceived.
Conceptually, the term pre-clinical research alludes to potential clin-
ical applications at least being considered, if not intended. However,
pre-clinical research is a necessary, but not sufﬁcient prerequisite for
future applications, and such applications do certainly not automatic-
ally follow from allowing pre-clinical research, as is outlined in the
Background document.
‘Comprehensive’ genetic testing of embryos (preimplantation genetic
testing, PGT) using whole genome sequencing (WGS) might be an inte-
gral part of adequate pre-clinical research on the safety and speciﬁcity
of GLGE to investigate potential off-target effects. The issue of how to
handle possible incidental ﬁndings regarding the genetic makeup of the
providers of the gametes or embryos should be addressed in the
informed consent process, taking account of relevant guidelines.
According to the Clinical Trials Regulation EU No.536/2014, Article
90, modiﬁcations to the germline are not allowed. It must be clariﬁed
what this implies for pre-clinical studies.
Reproductive germline gene editing
Potentially in the future, depending on the outcomes of basic and
pre-clinical research and taking account of societal views, risks and
implications (see below), moving the technique towards the clinic may
be considered. If so, this should be embedded in a formal research tra-
jectory. According to the Clinical Trials Regulation EU No.536/2014,
Article 90 ‘No gene therapy clinical trials may be carried out which result
in modiﬁcations to the subject’s germ line genetic identity’. The implica-
tion of this regulation, is that adequate clinical GLGE research is impos-
sible in the European Union (EU). Potentially this would also apply to
pre-clinical research. Meanwhile, the clinical applications may take place
outside the EU and in some cases may be carried out without proper
research protocols and oversight. Given the technological development
and the ethical analysis as described in the background document compar-
ing GLGE to other available reproductive options, the time has come to
discuss the rationale and consequences of the Clinical Trials Regulation.
If shown to be safe and effective, clinical GLGE may come to have
important beneﬁts for prospective parents at high risk of having a child
affected by a serious genetic disorder and for whom, for example,
PGD is not a real option.
Categorical deontological objections to clinical GLGE—in terms of
being at odds with, for example, naturalness, human dignity or the
preservation of the human gene pool as a common heritage—are
often used both in public debate and legal discourse. While these
objections may be relevant for possible (mostly rather theoretical)
enhancement-like applications of GLGE, they seem unconvincing when
it comes to possible applications of GLGE with a clear therapeutic or
preventive aim, as elaborated in the Background document. A better
understanding of these objections, and the context in which they are
used, is needed to inform future policy decisions, public debate and
the counselling of individual patients.
Consequentialist objections to reproductive GLGE, regarding both
health risks and societal concerns, merit more scrutiny and debate.
Health risks
In the context of GLGE health risks should be taken to refer to not only
those affecting the ﬁrst generation but also possible subsequent ones.
Different types of possible adverse effects (off-target and pleiotropic, gen-
etic and epigenetic) need investigation. In view of the many unknowns,
any use of GLGE methods for clinical purposes, including any reproduct-
ive use of gametes derived from edited pluripotent somatic cells, should
be regarded as premature and therefore at present unacceptable.
Clinical applications can only become morally justiﬁed if adequate
pre-clinical safety research, including (human) embryo research, shows
clinical GLGE to be sufﬁciently safe and efﬁcient. The proper standard
for the evaluation of possible residual risks (‘how safe is safe enough in
order to start clinical applications?’) needs speciﬁc assessment after
further debate and clariﬁcation.
If comprehensive PGT of edited embryos on the basis of WGS
would be included as a safeguard in future clinical GLGE, this testing
should be focused on possible off-target effects, taking into account
potential mosaicism. A possible broadening of the interpretation of
the raw data generated by such PGT raises complex additional ethical
issues and would need further multidisciplinary analysis and debate.
The proportionality of such broader analysis should not be taken for
granted, and it may generate more questions than answers, as elabo-
rated in the Background document.
Furthermore, any potential future reproductive GLGE would require
prospective data collection of reproductive outcomes and long-term fol-
low-up studies on the health of children thus conceived. Possible practical
3Recommendations for human germline gene editing
Downloaded from https://academic.oup.com/hropen/article-abstract/2018/1/hox025/4797563
by guest
on 14 January 2018
barriers and limits (in terms of, for example, lack of funding or tensions
between long-term follow-up and familial and children’s privacy) may ren-
der this challenging, as with long-term follow-up of children conceived
through new reproductive technologies generally.
Societal concerns
The major societal risks often mentioned in this context are inequity,
the undermining of reproductive autonomy, the position of people
affected with impairments or disabilities and possible misuse of GLGE
for non-medical applications.
The disability rights critique forcefully reminds society of its responsibil-
ities towards people with disabilities, more particularly its obligation to
remove barriers for inclusion, but it should not be used as an argument
against the development of medical therapies, including gene editing, irre-
spective of whether it concerns somatic gene editing or GLGE.
Equal access to health care has to be decided at the level of society
as a whole. Public funding, as some countries have provided for PGD,
can mitigate the concerns regarding inequity. If limited funding is avail-
able for health care, prioritization is needed. It is conceivable that som-
atic gene editing will be prioritized over GLGE as many serious health
problems could be targeted and it might be a proportionate (albeit
temporary) approach to treatment. The deﬁnition and speciﬁcation of
seriousness may be a challenge and needs to be assessed within spe-
ciﬁc national ethical rules and regulations.
Reproductive autonomy should be maintained and respected by both
adequate counselling and provisions for disabled people. Moreover, while
some fear the undermining of reproductive autonomy, it should be noted
that GLGE may well promote the reproductive autonomy of prospective
parents at high risk of having a child affected with a serious disorder, as it
would increase the number of reproductive options (see below).
In order to ensure strong societal and professional oversight, the
experience with regulating PGD and other reproductive technologies
should help build a sound strategy for regulating possible future clinical
applications of GLGE, including a licensing system for clinics involved,
quality controls and obligatory regular reporting by licensed clinics of
their handling of requests for GLGE. If clinical GLGE does come to be
considered sound, priority should be given to the editing of highly
penetrant genes causing serious disorders. As the distinction between
serious and less serious disorders is unclear, feeding fears of a slippery
slope, further multidisciplinary reﬂection on the demarcation of serious
disorders is needed. In addition, the distinction between therapy and
enhancement is not always clear-cut and decisions will need to be
made about intermediate subtypes of medical enhancement, such as
strengthening the human immune system or editing carrier status for
recessive disorders or structural aberrations. With regard to fears
about possible future ‘designer babies’, it is important to acknowledge
that the prospect of enhancing complex traits (such as intelligence) is
to a large extent science ﬁction, and that possible efforts to enhance
traits would run a disproportional risk of antagonistic (harmful) pleio-
tropic effects. Public debate and education is needed to lower the risk
of commercial companies seeking to exploit prospective parents’
(unrealistic) preference for a ‘perfect child’.
In view of the medical and societal risks of, and concerns regarding,
GLGE it is important to take account of other reproductive options for
people at high risk of having an affected child. Considering the preference
of most prospective parents to have a healthy child who is genetically
related to both of them, PGD aimed at the selective transfer of an
unaffected embryo may be a good ‘preventive’ option in most cases. Still,
there may be situations where GLGE might be justiﬁed, depending upon
the genetic disorder under consideration, the prospective parents’ gen-
etic makeup, their experiences with clinical PGD, their weighing of the
possible risks and burdens of a further cycle of IVF/PGD, and their moral
and religious preferences, including their possible wish to minimize
embryo loss. A further ethical and societal evaluation of relevant aspects,
including the possible health risks of GLGE, is needed to deﬁne the
potential future indications for clinical GLGE as an alternative to PGD
that aims to selectively transfer an unaffected embryo.
Possible future routine comprehensive PGT of IVF-embryos using
WGS, aimed at selecting ‘the best embryo’ for transfer, needs pro-
active scientiﬁc, ethical and societal debate. Such testing could well,
assuming a further improvement of the efﬁciency of editing (post-zyg-
otic) embryos, function as a driver for future routine GLGE, at least
among some (wealthy) social groups. After all, there will always be
potentially pathogenic variants, as all embryos, like humans, are ‘fellow
mutants’. While this scenario would be problematic in view of the
pleiotropic risks of GLGE, it does at the same time urge society even
more strongly to engage in a more principled debate about the ethics
of, and policymaking regarding, the conceptually and morally grey area
between therapeutic, preventive and enhancement GLGE.
Governance
A process of ongoing public debate about material and procedural ethical
and societal issues raised by both non-reproductive and reproductive
human GLGE is of the utmost importance. Such debate should be based
on sound scientiﬁc evidence as well as sound ethical, legal and social
reﬂection in such a manner that many different stakeholders can under-
stand and take part. A strategic plan, including the funding, and practical
and temporal aspects should be devised to ensure that such debates are
prioritized and undertaken at the same time that the science and policy
discussions evolve. Multi-stakeholder debates should be inclusive; apart
from scientists and clinicians, other stakeholders should be invited to par-
ticipate, including patients’ organizations, different lay groups of the pub-
lic, policymakers and scholars in the medical humanities.
These current Recommendations build a ﬁrst, joint, contribution of
both ESHRE and ESHG to the suggested ongoing trajectory of profes-
sional and public deliberations. The Recommendations are of a provi-
sional nature and are to be evaluated regularly and systematically to
facilitate ﬂexibility in approaches and regulation.
Acknowledgements
We thank the persons who commented on earlier versions of
these Recommendations or the Background document to these
Recommendations, especially the members of the Public and Professional
Policy Committee of ESHG and Ethics Committee of ESHRE and Erika
Kleiderman, Bartha Maria Knoppers, Raul Piña-Aguilar, Alessandra
Renieri, Gijs Santen and Kirmo Wartiovaara.
Authors’ roles
G.dW. wrote the paper. All other co-authors participated in one or
more tele-conferences or meetings to discuss the draft, reviewed the
article and made corrections and suggestions for improvement.
4 de Wert et al.
Downloaded from https://academic.oup.com/hropen/article-abstract/2018/1/hox025/4797563
by guest
on 14 January 2018
Funding
No external funding was obtained. Costs for the meetings were cov-
ered by European Society of Human Reproduction and Development
and the European Society of Human Genetics.
Conﬂict of interest
None declared.
References
DeWert G, Heindryckx B, Pennings G, Clarke A, Eichenlaub-Ritter U, Van El
CG, Forzano F, Goddijn M, Howard H, Radojkovic D et al. Responsible
innovation in human germline gene editing. Background document to the
recommendations of the ESHG and ESHRE. Eur J Hum Genet 2017a.
De Wert G, Heindryckx B, Pennings G, Clarke A, Eichenlaub-Ritter U,
Van El CG, Forzano F, Goddijn M, Howard H, Radojkovic D et al.
Responsible innovation in human germline gene editing. Background
document to the recommendations of the ESHG and ESHRE. Hum
Reprod Open 2017b.
5Recommendations for human germline gene editing
Downloaded from https://academic.oup.com/hropen/article-abstract/2018/1/hox025/4797563
by guest
on 14 January 2018
